D75.1 Secondary polycythemia

Name of the Condition

• Secondary polycythemia

Summary

Secondary polycythemia is a condition characterized by an increased production of red blood cells (erythrocytosis) in response to an underlying cause, such as chronic hypoxia or excessive erythropoietin production. Unlike primary polycythemia, it is not a clonal disorder of the bone marrow but rather a reactive process. The elevation in red blood cell mass can lead to increased blood viscosity, potentially causing symptoms or complications related to impaired circulation.

Causes

Secondary polycythemia arises from factors that stimulate red blood cell production, including chronic hypoxia (e.g., from lung disease, high altitude, or sleep apnea), tumors that produce erythropoietin, or certain medications. Other causes may include chronic carbon monoxide exposure, renal disease, or endocrine disorders. The underlying condition drives the overproduction of red blood cells.

Risk Factors

• Chronic hypoxic conditions (e.g., chronic obstructive pulmonary disease, high altitude residence).
• Tumors or cysts that secrete erythropoietin.
• Chronic kidney disease or renal transplantation.
• Certain medications (e.g., androgens, erythropoietin-stimulating agents).
• Smoking or exposure to carbon monoxide.

Symptoms

• Headaches, dizziness, or lightheadedness due to increased blood viscosity.
• Visual disturbances or blurred vision.
• Fatigue, weakness, or shortness of breath.
• Pruritus (itching), particularly after warm baths or showers.
• In severe cases, symptoms of thrombosis, such as chest pain or limb swelling.

Diagnosis

Diagnosis involves confirming elevated hemoglobin or hematocrit levels (typically >18 g/dL in men or >16 g/dL in women) and identifying an underlying cause. Testing may include a complete blood count, arterial blood gas analysis, erythropoietin levels, and imaging or endoscopic studies to detect tumors or hypoxic sources. Bone marrow evaluation is usually not required unless primary polycythemia is suspected.

Treatment Options

Treatment focuses on addressing the underlying cause. For hypoxia-related cases, supplemental oxygen or management of lung disease may be used. Tumors producing erythropoietin may require surgical removal or chemotherapy. Phlebotomy (blood removal) can reduce blood viscosity in symptomatic patients, and hydration is recommended to lower hematocrit. Medications to suppress erythropoiesis may be considered in specific cases.

Prognosis and Follow-Up

Prognosis depends on the underlying condition and its response to treatment. If the cause is reversible (e.g., smoking cessation or tumor removal), polycythemia may resolve. Chronic or untreated cases may lead to complications like thrombosis. Regular monitoring of hemoglobin/hematocrit and management of the underlying disorder is essential for long-term outcomes.

Complications

• Thrombotic events (e.g., deep vein thrombosis, stroke) due to increased blood viscosity.
• Hypertension or cardiovascular strain.
• Peptic ulcer disease or gout (less common).
• Worsening of underlying conditions (e.g., heart failure in chronic hypoxia).

Lifestyle & Prevention

• Avoid smoking or exposure to carbon monoxide.
• Manage chronic conditions (e.g., sleep apnea, lung disease) with appropriate treatment.
• Stay hydrated to reduce blood viscosity.
• Limit alcohol consumption, which may exacerbate symptoms.
• Regular exercise, if tolerated, to improve oxygen utilization (under medical guidance).

When to Seek Professional Help

Seek medical attention if you experience persistent headaches, dizziness, shortness of breath, or signs of thrombosis (e.g., chest pain, leg swelling). Prompt evaluation is necessary if polycythemia is suspected, especially if symptoms worsen or new complications arise.

Tips for Medical Coders

Document the underlying cause of secondary polycythemia (e.g., chronic hypoxia, tumor) to support code assignment. Ensure clinical correlation between elevated red blood cell parameters and the identified trigger. Avoid using this code for primary polycythemia (e.g., polycythemia vera) or unspecified cases. Code D75.1 is appropriate when the condition is secondary and the cause is documented.